High-sensitivity cardiac troponin and the diagnosis of myocardial infarction in patients with kidney impairment.

Peter J Gallacher; Eve Miller-Hodges; Anoop SV Shah ORCID logo; Tariq E Farrah; Nynke Halbesma; James P Blackmur; Andrew R Chapman; Philip D Adamson; Atul Anand; Fiona E Strachan; +18 more... Amy V Ferry; Kuan Ken Lee; Colin Berry; Iain Findlay; Anne Cruickshank; Alan Reid; Alasdair Gray; Paul O Collinson; Fred S Apple; David A McAllister; Donogh Maguire; Keith AA Fox; Catriona Keerie; Christopher J Weir; David E Newby; Nicholas L Mills; Neeraj Dhaun; High-STEACS Investigators; (2022) High-sensitivity cardiac troponin and the diagnosis of myocardial infarction in patients with kidney impairment. Kidney international, 102 (1). pp. 149-159. ISSN 0085-2538 DOI: 10.1016/j.kint.2022.02.019
Copy

The benefit and utility of high-sensitivity cardiac troponin (hs-cTn) in the diagnosis of myocardial infarction in patients with kidney impairment is unclear. Here, we describe implementation of hs-cTnI testing on the diagnosis, management, and outcomes of myocardial infarction in patients with and without kidney impairment. Consecutive patients with suspected acute coronary syndrome enrolled in a stepped-wedge, cluster-randomized controlled trial were included in this pre-specified secondary analysis. Kidney impairment was defined as an eGFR under 60mL/min/1.73m2. The index diagnosis and primary outcome of type 1 and type 4b myocardial infarction or cardiovascular death at one year were compared in patients with and without kidney impairment following implementation of hs-cTnI assay with 99th centile sex-specific diagnostic thresholds. Serum creatinine concentrations were available in 46,927 patients (mean age 61 years; 47% women), of whom 9,080 (19%) had kidney impairment. hs-cTnIs were over 99th centile in 46% and 16% of patients with and without kidney impairment. Implementation increased the diagnosis of type 1 infarction from 12.4% to 17.8%, and from 7.5% to 9.4% in patients with and without kidney impairment (both significant). Patients with kidney impairment and type 1 myocardial infarction were less likely to undergo coronary revascularization (26% versus 53%) or receive dual anti-platelets (40% versus 68%) than those without kidney impairment, and this did not change post-implementation. In patients with hs-cTnI above the 99th centile, the primary outcome occurred twice as often in those with kidney impairment compared to those without (24% versus 12%, hazard ratio 1.53, 95% confidence interval 1.31 to 1.78). Thus, hs-cTnI testing increased the identification of myocardial injury and infarction but failed to address disparities in management and outcomes between those with and without kidney impairment.


picture_as_pdf
Gallacher_etal_2022_High-sensitivity-cardiac-troponin-and.pdf
subject
Published Version
Available under Creative Commons: 4.0

View Download

Atom BibTeX OpenURL ContextObject in Span Multiline CSV OpenURL ContextObject Dublin Core Dublin Core MPEG-21 DIDL EndNote HTML Citation JSON MARC (ASCII) MARC (ISO 2709) METS MODS RDF+N3 RDF+N-Triples RDF+XML RIOXX2 XML Reference Manager Refer Simple Metadata ASCII Citation EP3 XML
Export

Downloads